Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec 6;73(11):e3980-e3981.
doi: 10.1093/cid/ciaa1210.

Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al

Boghuma K Titanji  1 , Monica M Farley  1   2 , Raymond F Schinazi  3 , Vincent C Marconi  1   2   4   5
Affiliations
Comment

Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al

Boghuma K Titanji et al. Clin Infect Dis. .
No abstract available

PubMed Disclaimer

Comment on

  • Reply to Jorgensen, et al.
    Titanji BK, Farley MM, Schinazi RF, Marconi VC. Titanji BK, et al. Clin Infect Dis. 2021 Dec 6;73(11):e3978-e3979. doi: 10.1093/cid/ciaa1212. Clin Infect Dis. 2021. PMID: 32797235 Free PMC article. No abstract available.
  • Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy?
    Jorgensen SCJ, Burry L, Tse CLY, Dresser LD. Jorgensen SCJ, et al. Clin Infect Dis. 2021 Dec 6;73(11):e3978-e3979. doi: 10.1093/cid/ciaa1208. Clin Infect Dis. 2021. PMID: 32797237 Free PMC article. No abstract available.

References

    1. Vallejo-Yagüe E, Weiler S, Micheroli R, Burden AM. Thromboembolic safety reporting of tofacitinib and baricitinib: an analysis of the WHO VigiBase. Drug Saf [Epub ahead of print]. Available at: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa879/586.... Accessed 23 July 2020. doi: 10.1007/s40264-020-00958-9. - DOI - DOI - PubMed
    1. Bronte V, Ugel S, Tinazzi E, et al. . Baricitinib restrains the immune dysregulation in COVID-19 patients. medRxiv [preprint] June 30, 2020. [cited July 23, 2020, doi: 10.1101/2020.06.26.20135319 - DOI - PMC - PubMed
    1. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect [Epub ahead of print]. Available at: https://www.journalofinfection.com/article/S0163-4453(20)30228-0/fulltext. Accessed 23 July 2020. doi: 10.1016j.jinf.2020.04.017. - PMC - PubMed
    1. Cao Y, Wei J, Zou L, et al. . Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 2020; 146:137–46.e3. - PMC - PubMed
    1. Giudice V, Pagliano P, Vatrella A, et al. . Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study. Front Pharmacol 2020; 11:857. - PMC - PubMed